Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06657404

The Modified "Pills-in-the-Pocket" Strategy

Led by Yumei Xue · Updated on 2024-10-24

328

Participants Needed

1

Research Sites

9 weeks

Total Duration

On this page

Sponsors

Y

Yumei Xue

Lead Sponsor

B

Beijing Anzhen Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a multicentre, prospective, randomised controlled study of 328 patients with non-paroxysmal AF (within 5 years of first diagnosis of AF) with recurrent atrial arrhythmias after first catheter ablation, randomly divided in a 1:1 ratio into a study group treated with triple AADs (amiodarone + bisoprolol + digoxin) and a control group treated with conventional AADs (amiodarone + bisoprolol + digoxin). The study group was treated with triple AADs (amiodarone + bisoprolol) and the control group was treated with conventional AADs (amiodarone + bisoprolol) with the aim of comparing the efficacy and safety of the two groups in terms of reversion of SR, which may provide an effective option of pocket drug reversion for patients with recurrence of SR after AF catheter ablation. Translated with DeepL.com (free version)

CONDITIONS

Official Title

The Modified "Pills-in-the-Pocket" Strategy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Non-valvular, non-paroxysmal atrial fibrillation within 5 years of first diagnosis
  • Recurrent atrial arrhythmia lasting more than 24 hours after the first catheter ablation and not self-terminating
  • Patients not currently taking antiarrhythmic drugs after the procedure and agreeing to receive them without contraindications, or patients off such drugs for more than 1 month
Not Eligible

You will not qualify if you...

  • Previous cardiac surgery such as bypass grafting or valve replacement
  • Presence of cardiomyopathy (hypertrophic, dilated, ischemic, etc.)
  • Left atrium diameter 50mm or greater or valvular changes from rheumatic heart disease
  • History of abnormal thyroid function
  • Severe liver or kidney failure (eGFR less than 15, Child Class 3) or history of dialysis
  • Heart rate below 60 bpm or any degree of atrioventricular block or multiple branch block after catheter ablation
  • Left ventricular ejection fraction below 40% or NYHA class III-IV after catheter ablation
  • Participation in another drug or device clinical trial during the same period
  • Other abnormalities or diseases deemed exclusionary by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

Actively Recruiting

Loading map...

Research Team

Y

Yumei Xue, phD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

The Modified "Pills-in-the-Pocket" Strategy | DecenTrialz